Daniel A. de Boer

Daniel is the Founder and Chief Executive Officer since the incorporation in 2012. Daniel is a serial entrepreneur and passionate advocate for rare disease patients. After one of his children was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Under Daniel’s leadership, ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases and raised over $500M in funding, including an IPO on Nasdaq. Before founding ProQR, Daniel was the founder and Chief Executive Officer of several technology companies. Daniel is also a strategic advisor at Hybridize Therapeutics, Frame Therapeutics, Meatable, Algramo, Xinvento, and a member of the advisory board at the Termeer Foundation. In 2018 Daniel was named "Emerging Entrepreneur of the Year" by EY. In 2019 Daniel was selected for the Young Global Leader program at the World Economic Forum.